Bristol-Myers Squibb and AstraZeneca report positive dapagliflozin data
28 June 2011 00:00 in Pharmaceutical Company Product News
Bristol-Myers Squibb and AstraZeneca have published positive results from a clinical study of dapagliflozin, their new treatment for type 2 diabetes.
The developmental drug has been evaluated in a phase III clinical trial, in which a combination of dapagliflozin and metformin was compared to a therapy option involving a common sulphonylurea treatment.
It was found that the dapagliflozin regimen was able to deliver sustained reductions of blood sugar levels among adult patients compared to those in the control group.
Dr Michael Nauck, head of the diabetes centre at Bad Lauterberg, said: "As we advance our knowledge of how SGLT2 inhibitors may work as a potential treatment ... long-term data becomes critical to assess a compound's safety and its ability to sustain glycaemic control."
A European marketing authorisation application for the new drug has already been validated earlier this year.
Last week, Bristol-Myers Squibb published positive data from a phase III trial of Eliquis, the atrial fibrillation treatment it has developed alongside Pfizer.
Other news stories from 28/06/2011
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency